Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 2/20 | 0.50 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 3/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23260551 | 0.85 | NR2E1 (0.43) | LDHANR2E1HTR2APDE2ASLC9A1 | |
| SCHEMBL26529830 | 0.82 | IRAK4 (0.44) | NR2E1HTR2APDE2ASLC9A1ALDH1A1 | |
| SCHEMBL26530022 | 0.81 | IRAK4 (0.44) | NR2E1HTR2APDE2ASLC9A1ALDH1A1 | |
| SCHEMBL26530054 | 0.79 | NR2E1 (0.43) | NR2E1HTR2APDE2ASLC9A1ALDH1A1 | |
| SCHEMBL26529996 | 0.79 | HTT (0.47) | ALDH1A1KDM4ENAMPTKMT2A | |
| SCHEMBL26530029 | 0.78 | NR2E1 (0.43) | NR2E1HTR2APDE2ASLC9A1ALDH1A1 | |
| SCHEMBL26530043 | 0.77 | PDE2A (0.41) | NR2E1HTR2APDE2ASLC9A1ALDH1A1 | |
| SCHEMBL26535536 | 0.77 | HDAC4 (0.47) | NR2E1HTR2APDE2ASLC9A1ALDH1A1 | |
| SCHEMBL26530033 | 0.76 | NR2E1 (0.49) | NR2E1ALDH1A1KDM4ESMN1; SMN2MGLL | |
| SCHEMBL26530035 | 0.75 | PLAT (0.38) | NR2E1HTR2APDE2ASLC9A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | YTHDF1, YTHDF3, YTHDF2 | LDHA 3964/4885NR2E1 2168/4885HTR2A 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.